earnings
confidence high
sentiment positive
materiality 0.70
Anebulo Pharma Q1 net loss narrows to $2.2M; awarded $1.9M NIDA grant for selonabant
Anebulo Pharmaceuticals, Inc.
2025-Q1 EPS reported
-$0.08
- Net loss of $2.2M ($0.08/sh) vs $2.5M ($0.10/sh) in prior year quarter.
- Operating expenses of $2.4M, down from $2.5M year-over-year.
- Cash $1.4M at Sept 30, 2024; access to $10M loan facility.
- Awarded $1.9M NIDA grant to support IV selonabant development.
- Plans to enroll first healthy volunteer in IV study in first half of 2025.